Peer Re­view: Ru­bius re­cruits BD chief; Epizyme hires No­var­tis vet as CFO

Ru­bius Ther­a­peu­tics — clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pa­ny de­vel­op­ing a new class of med­i­cines called red cell ther­a­peu­tics — made the ad­di­tion of Kris Elverum to its se­nior lead­er­ship team as SVP of busi­ness de­vel­op­ment and strat­e­gy. Elverum joins the com­pa­ny from Turn­stone Bi­o­log­ics and has pre­vi­ous­ly served at SQZ Biotech, No­var­tis and McK­in­sey & Co

→ As Epizyme preps a tran­si­tion to the com­mer­cial stage — which could come as ear­ly as next Jan­u­ary if the FDA comes through — it’s in­stalling Pao­lo Tombe­si as CFO. A No­var­tis vet, Tombe­si has over­seen a sim­i­lar tran­si­tion for In­smed, help­ing launch a sub­sidiary in Japan and bring­ing in more than $1 bil­lion by Epizyme’s count. Aside for the sar­co­ma ap­pli­ca­tion, now un­der pri­or­i­ty pre­view, a sec­ond NDA for tazeme­to­stat is slat­ed for lat­er this year, he added.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.